Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia. The ACC is the world’s leading educational meeting for healthcare professionals involved in the research and management of patients with cough.
Christopher Bryan, PhD, Vice President of Research and Operations at Algernon Pharmaceuticals, will present “An update on NP-120 (ifenprodil): A subunit-selective NMDA receptor antagonist for the treatment of cough” during a thematic oral session on antitussive drug development programs. The focus of the talk will be on data from AGN-120-1, the Company’s Phase 2a clinical trial in Idiopathic Pulmonary Fibrosis (IPF) and associated cough.
The Company previously reported that Ifenprodil, given three times daily in subjects with IPF and an associated cough, reduced geometric mean cough counts by 32.0% at 4 weeks (p = 0.023) and 39.5% at 12 weeks (p = 0.001) compared to baseline. Further details on the study will be presented.
9th American Cough Conference
Date and Time: Saturday, June 10 at 2:05 PM EDT
Conference link: https://www.americancoughconference.com/
The presentation will be available to registered attendees on the ACC digital platform during and after the conference.
About NP-120 (Ifenprodil)
Ifenprodil selectively inhibits N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. NMDA receptors are ion-channels found within the central and peripheral nervous system, including the area of the brain responsible for coordinating the cough reflex. They are highly implicated in events such as neuronal plasticity (strengthening of neural pathways) and excitotoxicity (neurotoxic cascade resulting in neuron death).
By inhibiting NMDA receptors, Ifenprodil can diminish excitability of neurons and prevent the relaying of information along neuronal circuitry, including the cough reflex. Ifenprodil may also inhibit the neuroplastic enhancement of central and peripheral cough response neurons.
About Algernon Pharmaceuticals Inc.
Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury.